Morphine Equivalent Daily Dose (MEDD) Calculator

How to Use This Calculator

1. Select opioid type and enter daily dose for each concurrent opioid.
2. Total MEDD, CDC risk level, and naloxone recommendation appear instantly.
3. MME Reference Table tab: quickly look up conversions between opioids.
4. Taper Planner tab: calculate weeks to reach target MEDD at a given taper rate.
5. Professional tier: full CDC 2022 guideline assessment and clinical action plan.

Formula

Example

Frequently Asked Questions

• What is MEDD and why is it clinically important? ▼
  Morphine Equivalent Daily Dose (MEDD), also called Morphine Milligram Equivalent (MME), is a standardized unit that converts the dose of any opioid to the equivalent analgesic dose of oral morphine. Because different opioids have vastly different potencies — for example, fentanyl is approximately 100 times more potent than oral morphine by weight, while codeine is approximately 6–7 times less potent — expressing all opioid prescribing in MEDD units allows meaningful comparison of total opioid burden across different drugs and routes. MEDD is calculated by multiplying the daily dose of each opioid by its equianalgesic conversion factor and summing all contributions. The clinical importance of MEDD lies primarily in overdose risk assessment. The 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain identified ≥50 MEDD as a threshold warranting co-prescription of naloxone and reassessment of the risk-benefit ratio, and ≥90 MEDD as a level where risks of overdose death substantially increase. Research from Washington State showed a dose-dependent increase in overdose mortality, with patients on ≥100 MEDD having approximately 9 times the overdose risk of those on lower doses. MEDD is now required for opioid monitoring programs, prescription drug monitoring programs (PDMPs), and is integrated into many electronic health record-based opioid safety alerts.
• What are the standard opioid conversion factors? ▼
  Equianalgesic conversion ratios represent the doses of different opioids that provide equivalent analgesia to 10 mg of parenteral (IV/IM) morphine, derived from published equianalgesic tables and confirmed in controlled trials. The standard oral morphine is the reference at a conversion factor of 1.0. Key conversion factors (daily dose multiplied by factor = MEDD) include: oral oxycodone ×1.5 (10 mg oxycodone = 15 mg oral morphine MEDD); oral hydrocodone ×1.0 (1:1 with oral morphine); oral hydromorphone ×4.0 (4 mg hydromorphone = 16 mg MEDD); intravenous morphine ×3.0 (10 mg IV = 30 mg oral morphine MEDD); intravenous hydromorphone ×20 (1 mg IV hydromorphone = 20 mg MEDD); oral codeine ×0.15 (60 mg codeine = 9 mg MEDD); oral tramadol ×0.1 (100 mg tramadol = 10 mg MEDD); fentanyl transdermal patch ×2.4 per mcg/hr (25 mcg/hr patch = 60 mg/day MEDD); oral tapentadol ×0.4 (100 mg tapentadol = 40 mg MEDD). Methadone is excluded from standard conversion tables because its conversion ratio is highly dose-dependent (ranging from 4:1 at low doses to 12:1 or higher at doses >100 mg/day) and requires specialist management. These factors are approximations and individual variation in pharmacokinetics means actual equianalgesic requirements may differ by 30–50% between patients.
• What does the CDC 2022 guideline say about high MEDD prescribing? ▼
  The 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain (updated from the 2016 version) provides specific guidance regarding MEDD thresholds. The guideline recommends that when starting opioid therapy for acute pain, immediate-release opioids should be used at the lowest effective dose and for the shortest duration. For patients on chronic opioid therapy, clinicians should use caution when prescribing ≥50 MEDD and should avoid exceeding 90 MEDD or carefully justify and document the decision to do so. The guideline explicitly recommends offering naloxone to all patients receiving opioids, particularly those at ≥50 MEDD, those with history of overdose, those with concurrent benzodiazepine use, or those with substance use disorder history. Concurrent benzodiazepine use multiplies overdose risk substantially — the combination of opioids and benzodiazepines was associated with a 3.9-fold increase in overdose death in a large VA database study. The 2022 guideline also notes that the 90 MEDD threshold should not be used as a hard ceiling that triggers abrupt discontinuation in patients on stable high-dose chronic therapy — rather, it should trigger patient-centered conversations about risks, benefits, non-opioid alternatives, and slow dose reduction where appropriate.
• How is fentanyl patch dose converted to MEDD? ▼
  Fentanyl transdermal patches are labeled in micrograms per hour (mcg/hr) release rate, which requires a different conversion approach than oral or IV opioids. The standard conversion used by the CDC, FDA, and most clinical references is that each 1 mcg/hr of fentanyl patch delivery is approximately equivalent to 2.4 mg/day of oral morphine MEDD. Therefore: 12 mcg/hr patch ≈ 29 mg/day MEDD; 25 mcg/hr patch ≈ 60 mg/day MEDD; 50 mcg/hr patch ≈ 120 mg/day MEDD; 75 mcg/hr patch ≈ 180 mg/day MEDD; 100 mcg/hr patch ≈ 240 mg/day MEDD. This means that a single 100 mcg/hr fentanyl patch places a patient firmly in the very high MEDD risk zone (≥200 MEDD). Patients stabilized on high-dose fentanyl patches are at substantial overdose risk, particularly when dose adjustments are made, when other CNS depressants are added, or when patches are applied improperly (excessive heat increases release rate dramatically). Buprenorphine transdermal patches (Butrans) use a different calculation — approximately 12.6 mg MEDD per mcg/hr (e.g., 10 mcg/hr = 126 mg/day MEDD equivalence based on receptor binding studies), though buprenorphine's ceiling effect and partial agonist properties mean this conversion overestimates clinical opioid toxicity risk.
• What is the safest approach to opioid dose tapering? ▼
  Opioid tapering in patients with physical dependence requires careful planning to minimize withdrawal symptoms while reducing overdose risk. The 2022 CDC guideline emphasizes that abrupt discontinuation or rapid dose reduction should be avoided as it can precipitate severe withdrawal, patient distress, and has been associated with patients seeking illicit opioids. A slow taper of 10% or less of the current dose per week is recommended for patients who have been on chronic opioid therapy, particularly for more than a year. For patients on higher doses (≥90 MEDD), an even slower taper of 5–10% per month may be appropriate, especially in older patients and those with significant functional impairment. Practical steps include: switching to an extended-release formulation for smoother tapering, writing a specific taper schedule in the medical record, co-prescribing clonidine (0.1 mg bid-tid) for autonomic withdrawal symptoms (sweating, tachycardia, anxiety), considering adding non-opioid analgesics (NSAIDs, pregabalin, duloxetine, topical agents), and arranging behavioral health support. Withdrawal symptoms to monitor include: anxiety, restlessness, insomnia, yawning, diaphoresis, rhinorrhea, nausea, vomiting, myalgias, and piloerection. COWS (Clinical Opioid Withdrawal Scale) can be used to quantify withdrawal severity and guide management during medically supervised tapers.

Related Calculators